These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 22761000

  • 1. Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
    Wiśniowska B, Mendyk A, Fijorek K, Glinka A, Polak S.
    J Appl Toxicol; 2012 Oct; 32(10):858-66. PubMed ID: 22761000
    [Abstract] [Full Text] [Related]

  • 2. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
    Polak S, Wiśniowska B, Brandys J.
    J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
    [Abstract] [Full Text] [Related]

  • 3. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
    Mirams GR, Cui Y, Sher A, Fink M, Cooper J, Heath BM, McMahon NC, Gavaghan DJ, Noble D.
    Cardiovasc Res; 2011 Jul 01; 91(1):53-61. PubMed ID: 21300721
    [Abstract] [Full Text] [Related]

  • 4. Validation of visualized transgenic zebrafish as a high throughput model to assay bradycardia related cardio toxicity risk candidates.
    Wen D, Liu A, Chen F, Yang J, Dai R.
    J Appl Toxicol; 2012 Oct 01; 32(10):834-42. PubMed ID: 22744888
    [Abstract] [Full Text] [Related]

  • 5. A comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets.
    Shen MY, Su BH, Esposito EX, Hopfinger AJ, Tseng YJ.
    Chem Res Toxicol; 2011 Jun 20; 24(6):934-49. PubMed ID: 21504223
    [Abstract] [Full Text] [Related]

  • 6. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
    Inanobe A, Kamiya N, Murakami S, Fukunishi Y, Nakamura H, Kurachi Y.
    J Physiol Sci; 2008 Dec 20; 58(7):459-70. PubMed ID: 19032804
    [Abstract] [Full Text] [Related]

  • 7. Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
    Said TH, Wilson LD, Jeyaraj D, Fossa AA, Rosenbaum DS.
    J Cardiovasc Pharmacol; 2012 Aug 20; 60(2):165-71. PubMed ID: 22561361
    [Abstract] [Full Text] [Related]

  • 8. Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation.
    Nozaki Y, Honda Y, Tsujimoto S, Watanabe H, Kunimatsu T, Funabashi H.
    Toxicol Appl Pharmacol; 2014 Jul 01; 278(1):72-7. PubMed ID: 24742750
    [Abstract] [Full Text] [Related]

  • 9. hERG classification model based on a combination of support vector machine method and GRIND descriptors.
    Li Q, Jørgensen FS, Oprea T, Brunak S, Taboureau O.
    Mol Pharm; 2008 Jul 01; 5(1):117-27. PubMed ID: 18197627
    [Abstract] [Full Text] [Related]

  • 10. Impaired Inactivation of L-Type Ca2+ Current as a Potential Mechanism for Variable Arrhythmogenic Liability of HERG K+ Channel Blocking Drugs.
    Kim JG, Sung DJ, Kim HJ, Park SW, Won KJ, Kim B, Shin HC, Kim KS, Leem CH, Zhang YH, Cho H, Bae YM.
    PLoS One; 2016 Jul 01; 11(3):e0149198. PubMed ID: 26930604
    [Abstract] [Full Text] [Related]

  • 11. Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.
    Marostica E, Van Ammel K, Teisman A, Boussery K, Van Bocxlaer J, De Ridder F, Gallacher D, Vermeulen A.
    J Pharmacokinet Pharmacodyn; 2015 Dec 01; 42(6):659-79. PubMed ID: 26259721
    [Abstract] [Full Text] [Related]

  • 12. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
    Wang L, Wible BA, Wan X, Ficker E.
    J Pharmacol Exp Ther; 2007 Feb 01; 320(2):525-34. PubMed ID: 17095614
    [Abstract] [Full Text] [Related]

  • 13. A binary QSAR model for classification of hERG potassium channel blockers.
    Thai KM, Ecker GF.
    Bioorg Med Chem; 2008 Apr 01; 16(7):4107-19. PubMed ID: 18243713
    [Abstract] [Full Text] [Related]

  • 14. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
    Recanatini M, Poluzzi E, Masetti M, Cavalli A, De Ponti F.
    Med Res Rev; 2005 Mar 01; 25(2):133-66. PubMed ID: 15389727
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of human ether-a-go-go-related gene K+ channel and IKr of guinea pig cardiomyocytes by antipsychotic drug trifluoperazine.
    Choi SY, Koh YS, Jo SH.
    J Pharmacol Exp Ther; 2005 May 01; 313(2):888-95. PubMed ID: 15722405
    [Abstract] [Full Text] [Related]

  • 16. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
    Bottino D, Penland RC, stamps A, Traebert M, Dumotier B, Georgiva A, Helmlinger G, Lett GS.
    Prog Biophys Mol Biol; 2006 May 01; 90(1-3):414-43. PubMed ID: 16321428
    [Abstract] [Full Text] [Related]

  • 17. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
    Durdagi S, Duff HJ, Noskov SY.
    J Chem Inf Model; 2011 Feb 28; 51(2):463-74. PubMed ID: 21241063
    [Abstract] [Full Text] [Related]

  • 18. Computational investigations of hERG channel blockers: New insights and current predictive models.
    Villoutreix BO, Taboureau O.
    Adv Drug Deliv Rev; 2015 Jun 23; 86():72-82. PubMed ID: 25770776
    [Abstract] [Full Text] [Related]

  • 19. In silico prediction of hERG inhibition.
    Jing Y, Easter A, Peters D, Kim N, Enyedy IJ.
    Future Med Chem; 2015 Jun 23; 7(5):571-86. PubMed ID: 25921399
    [Abstract] [Full Text] [Related]

  • 20. Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic.
    Kang J, Compton DR, Vaz RJ, Rampe D.
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct 23; 389(10):1133-7. PubMed ID: 27530870
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.